The CDC's Advisory Committee on Immunization Practices voted to recommend RSV vaccination for high-risk adults aged 50-59, potentially benefiting approximately 30% of Americans in this age group with conditions like COPD, heart failure, and chronic kidney disease.
Insulin icodec, a once-weekly basal insulin analog, demonstrated positive safety and efficacy in phase 3 trials for type 2 diabetes, potentially reducing injection burden and improving adherence.